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Abstract
Background: Recent studies have shown that in addition to brain (or B-type) natriuretic peptide (BNP) and the N-terminal
proBNP fragment, levels of intact proBNP are also increased in heart failure. Moreover, present BNP immunoassays also
measure proBNP, as the anti-BNP antibody cross-reacts with proBNP. It is important to know the exact levels of proBNP in
heart failure, because elevation of the low-activity proBNP may be associated with the development of heart failure.
Methodology/Principal Findings: We therefore established a two-step immunochemiluminescent assay for total BNP
(BNP+proBNP) and proBNP using monoclonal antibodies and glycosylated proBNP as a standard. The assay enables
measurement of plasma total BNP and proBNP within only 7 h, without prior extraction of the plasma. The detection limit
was 0.4 pmol/L for a 50-ml plasma sample. Within-run CVs ranged from 5.2%–8.0% in proBNP assay and from 7.0%–8.4% in
total BNP assay, and between-run CVs ranged from 5.3–7.4% in proBNP assay and from 2.9%–9.5% in total BNP assay,
respectively. The dilution curves for plasma samples showed good linearity (correlation coefficients = 0.998–1.00), and
analytical recovery was 90–101%. The mean total BNP and proBNP in plasma from 116 healthy subjects were 1.461.2 pM
and 1.060.7 pM, respectively, and were 806129 pM and 42670 pM in 32 heart failure patients. Plasma proBNP levels
significantly correlate with age in normal subjects.
Conclusions/Significance: Our immunochemiluminescent assay is sufficiently rapid and precise for routine determination of
total BNP and proBNP in human plasma.
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Introduction
Brain (also known as B-type) natriuretic peptide (BNP) has been
used as a biomarker of heart failure for more than a decade [1].
Indeed, guidelines for the treatment of heart failure recommend
measurement BNP before making a diagnosis [2,3]. During the
process by which BNP is secreted from cardiac myocytes, its 108-
amino acid precursor, proBNP, is cleaved to form the 32-amino
acid peptide BNP and the 76-amino acid peptide N-terminal
proBNP fragment (NT-proBNP) [4]. Recent studies have shown
that in addition to BNP and the NT-proBNP, levels of uncleaved
proBNP are also considerably increased in plasma of patients with
heart failure [5,6,7]. This is noteworthy in part because the
immunoassay system currently being used to measure BNP levels
also detects proBNP, as the anti-BNP antibody cross-reacts with
proBNP. Consequently, the present assay system actually
measures not the active BNP level, but the total BNP
(BNP+proBNP) level [8].
It is important to know the proBNP level and/or proBNP/total
BNP ratio in heart failure, because proBNP has much less ability
to induce cGMP production (about 13–17%) than BNP, and
higher levels of the low-activity proBNP may be associated with
the development of heart failure [7]. Consistent with that idea, we
recently used the combination of gel-filtration and a fluorescent
immunoenzyme assay with BNP extracted from plasma to show
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that although proBNP/total BNP ratios vary widely in heart
failure, they are higher in cases of ventricular overload than in
atrial overload [6]. Unfortunately, the method used in that study
requires a great deal of time and effort, and extraction of the
peptide from plasma may cause underestimation of the proBNP
levels due to its high adsorptive property [9].
To overcome those shortcomings, we developed a sensitive
method to more quickly and easily measure levels of proBNP and
total BNP. Our idea was to make a sandwich immunoassay using a
common capture antibody recognizing the C-terminal region of
both BNP and proBNP and detection antibodies that recognize
different epitopes: the N-terminal region of proBNP and the ring
structure of BNP (Figure 1). Using this approach, we were able to
develop a sensitive immunochemiluminescent assay for proBNP
and total BNP in plasma. Here, we report on the assay’s
performance and its use to compare plasma levels of total BNP
and proBNP in healthy subjects and patients with heart failure. In
addition, we measured NT-proBNP and compared it with total
BNP and proBNP.
Materials and Methods
All patients provided written informed consent for all blood
sample analyses, and the protocol was approved by the Ethical
Committee of Kyoto University Graduate School of Medicine.
Sample analyses were also conducted in accordance with the
policies and procedures of the Institutional Review Board for the
use of human subjects in research at the Diagnostics Division of
Shionogi & Co., Ltd.
Peptides and Reagents
Glycosylated proBNP and recombinant proBNP were pur-
chased from Hytest Ltd. (Turk, Finland). The protein content was
determined by amino acid analysis. BNP was from Peptide
Institute, Inc. (Osaka, Japan). EZ-Link-sulfo-NHS-biotinylation
kits were from Pierce (Rockford, IL). Sulfo-HMCS (N-(8-
maleimidocapryloxy) sulfosuccinimide) was from Dojindo (Kuma-
moto, Japan). CDP/E (Disodium 2-chloro-5-(4-methoxy-
spiro{1,2-dioxetane-3,29-(59-chloro)-tricyclo [3,3,1,13,7]decan}-4-
yl)-1-phenyl phosphate) was from Applied Biosystems (Foster City,
CA).
Figure 1. Schematic diagram of the total BNP and proBNP assay systems. BC203(Fab’) is a common capture antibody in both systems. KY-
BNP-II(Fab’) is the detection antibody for the total BNP assay, and 18H5(Fab’) is the detection antibody for the proBNP assay. ALP: Alkaline
phosphatase; CDP-Star EmeraldII (Chemiluminescent Substrate): Disodium 2-chloro-5-(4-methoxy-spiro{1,2-dioxetane-3,29-(59-chloro)-tricyclo
[3,3,1,13,7]decan}-4-yl)-1-phenyl phosphate.
doi:10.1371/journal.pone.0053233.g001
Figure 2. Standard curves for the proBNP (open circle) and total BNP (closed circle) assays (A). Plasma dilution curves (B). Three
plasma samples collected from three heart failure patients were serially diluted with buffer.
doi:10.1371/journal.pone.0053233.g002
proBNP in Human Plasma
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e53233
Antibodies
The monoclonal antibodies BC203 (IgG1, k) and KY-BNP-II
(IgG1, k) were developed by Shionogi & Co., Ltd [10]. BC203 and
KY-BNP-II recognize the C-terminal region and the ring region of
BNP, respectively. The monoclonal antibody 18H5 was purchased
from Hytest Ltd. 18H5 recognizes a region (a.a. 13–20) of
proBNP. In the proBNP assay, the combination of BC203
(capture) and 18H5 (detection) was used because 18H5 is not
affected by glycosylation [11]. In the total BNP assay, the
combination of BC203 (capture) and KY-BNP-II (detection) was
used because KY-BNP-II recognizes nearly all bioactive BNPs
(Figure 1).
Preparation of BC203 coated immunoassay plates
BC203, which was the capture antibody in both assays, was
biotinylated using an EZ-Link-sulfo-NHS-biotinylation kit accord-
ing to the manufacturer’s instructions. The biotinylated BC203
(0.2 mg/well in 100 mL PBS) was added to streptavidin-coated
plates and incubated for 18 h at 4uC. After washing with a saline
containing 0.01 g/dL Tween 20 and 0.05 g/dL sodium azide
(Wash Buffer), the BC203 coated immunoassay plates were dried
in a desiccator.
Preparation of 18H5 (Fab’)-ALP and KY-BNP-II (Fab’)-ALP
The 18H5 and KY-BNP-II mAbs (IgG) were digested with
pepsin (IgG/pepsin = 1/0.05) for 4 h at 37uC in 100 mM citrate
buffer (pH 4.0) containing 100 mM NaCl. Thereafter, Fab’
solution was prepared by reduction with 10 mM 2-mercaptoethy-
lamine in 0.1 M phosphate buffer (pH 6.0) containing 5 mM
EDTA using the standard method [12]. Alkaline phosphatase
from calf intestine (ALP; 2.0 mg or 14.2 nmol; Kikkoman, Chiba,
Japan) in 0.475 mL 0.1 M Tris-HCl buffer (pH 7.0) containing
1 mM MgCl2 and 0.1 mM ZnCl2 was mixed with 31 mg
(71 nmol) of Sulfo-HMCS in 0.05 mL of water for 1.5 h on ice,
after which the HMCS-activated ALP was purified on a PD-10
column (GE Healthcare, Chalfont St. Giles, UK). Aliquots of
HMCS-activated ALP solution (0.96 mg in 0.192 mL) were each
added to 0.441 mg of the Fab’ in 0.15 mL of 0.1 M phosphate
buffer (pH 6.0) containing 5 mM EDTA and mixed for 16 h at
4uC. Unlabeled Fab’ antibody was removed using a TSKgel
3000SWxl column. The purified 18H5 (Fab’)-ALP and KY-BNP-
II (Fab’)-ALP were then diluted with a StabilZyme AP (BioFX
Lab.) and stored at 4uC until use.
Sandwich 2-step Chemiluminescent Enzyme
Immunoassay
After the BC203 coated immunoassay plates were washed with
a wash buffer, 50 mL of test sample or calibrator and 50 mL of
Assay Buffer (0.05 M Tris-HCl buffer (pH 7.4), 1 g/dL BSA,
0.01 g/dL Tween80, 1 mM MgCl2, 0.1 mM ZnCl2, 1000K IU/
mL Aprotinin, 0.1 mg/mL mouse gamma globulin, 0.9 g/dL
NaCl) were added to the wells. The plates were then incubated for
3 h at 25uC. After washing with wash buffer, 100 mL of detection
antibodies (18H5 (Fab’)-ALP, 100 ng/ml; KY-BNP-II (Fab’)-ALP,
416 ng/ml) were added to the wells. The plates were then
incubated for 1 h at 25uC, followed by washing with wash buffer
and addition of substrate (CDP/E) solution. The chemilumines-
cence from each well was then measured using a plate reader
(Wallac 1420 Arvo sx, Perkin Elmer, Inc., MA).
Study Patients
We collected blood samples from heart failure patients (18 men
and 14 women; age range, 34–84 years, mean age, 65611 years)
hospitalized at Kyoto University Hospital. The primary causes of
the heart failure were ischemic heart disease (n = 8), cardiomyop-
athy (n = 8), valvular heart disease (n = 7), pulmonary hypertension
(n= 7) and others (n = 2), which were diagnosed from the medical
history, physical examination and chest radiographic, electrocar-
Table 1. Recovery of standard glycosylated proBNP and BNP added to human plasma.
Added peptide concentration, pmol/L Recovery, % Recovery, %





Table 2. Effects of dilution on recovery rates with the proBNP and total BNP assay systems.
Dilution magnitude proBNP assay system total BNP assay system
Measured, pmol/L Recovery, % Measured, pmol/L Recovery, %
1 94 - 95 -
2 105 112 101 107
5 96 102 104 109
10 92 98 92 97
20 97 103 93 98
50 99 105 97 103
100 87 92 95 100
doi:10.1371/journal.pone.0053233.t002
proBNP in Human Plasma
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diographic, echocardiographic and/or cardiac catheterization
findings. Patients with symptomatic heart failure were under
medication, including angiotensin-converting-enzyme inhibitors/
angiotensin-receptor blockers, digitalis and diuretics. The New
York Heart Association (NYHA) functional classes were class I–II
(n = 19) and class III–IV (n= 13). Healthy subjects (61 men and 54
women; age range, 30–78 years, mean age, 50610 years) were
selected based on their normal physical, laboratory, chest
radiographic, electrocardiographic and echocardiographic find-
ings, and their BNP levels.
Plasma samples
Blood samples were drawn into plastic syringes and quickly
transferred to chilled tubes containing EDTA (1.5 mg/mL, blood)
and aprotinin (500 U/mL blood) and centrifuged at 16006 g for
20 min at 4uC. The obtained plasma samples were stored at
280uC until assayed.
Assay of plasma NT-proBNP levels
Plasma levels of NT-proBNP were measured using Elecsys
proBNP II assay system (Roche Diagnostics, Basel, Switzerland).
Gel filtration chromatography
Plasma samples were extracted using Sep-Pak C18 cartridges
(Waters, Milford, MA, USA) as previously described [6]. The
eluate was lyophilized and dissolved in 30% acetonitrile containing
0.1% TFA. The resultant solution (300 ml) was separated by gel
filtration HPLC on a Superdex 75 10/300 GL columns
(106300 mm62, GE Healthcare) in the same buffer at a flow
rate of 0.4 mL/min. The column effluent was fractionated every
minute into polypropylene tubes containing bovine serum albumin
(100 mg) and each fraction was analyzed using the total BNP and
proBNP assay systems. Because recent studies have shown that
glycosylated proBNP with a MW of about 30 K circulates in the
plasma [7], we examined the gel filtration positions at which
commercial recombinant proBNP and glycosylated proBNP, and
synthetic BNP were eluted to determine which is the major
molecular form of BNP in human plasma.
Deglycosylation enzyme treatment
We further analyzed the immunoreactive proBNP levels to
determine whether immunoreactive proBNP in plasma is glyco-
sylated. Eluate lyophilized after extraction on a Sep-Pak C18
column was dissolved in phosphate buffer and incubated with or
without a cocktail of deglycosylation enzymes for 24 h at 37uC, as
previously described [13]. The enzyme cocktail included O-
glycosidase (Roche Diagnostic) and neuraminidase (Roche Diag-
nostics) at final concentrations of 4.25 and 42.5 mU/mL,
respectively. These two enzymes were essential for the deglyco-
sylation, and the enzyme concentrations and incubation period
were selected based on the results of preliminary and previously
reported studies [11,13,14]. We then lyophilized the sample again
and dissolved it in 30% acetonitrile containing 0.1% TFA, after
which it was subjected to gel-filtration HPLC as described above.
Statistical Analysis
All values are expressed as means 6 SD. The statistical
significance of differences between 2 groups was evaluated using
Fisher’s exact test or unpaired Student’s t test, as appropriate.
Variables were compared among three groups using one-way
analysis of variance followed by Bonferroni’s multiple comparison
Table 3. Intra- and Inter-assay precision of the proBNP assay systems.
Added proBNP concentration
pmol/L Measured concentration pmol/L CV Bias
Mean S.D. % %
Intra-assay (n = 5) 2.0 2.0 0.2 8.0 2.0
25 25 1.3 5.2 0.0
100 101 5.5 5.4 1.0
Inter-assay (n = 15) 2.0 1.9 0.1 5.3 25.8
25 23 1.7 7.4 28.0
100 96 6.1 6.4 24.0
doi:10.1371/journal.pone.0053233.t003
Table 4. Intra- and Inter-assay precision of the total BNP systems.
Added BNP concentration pmol/LMeasured concentration pmol/L CV Bias
Mean S.D. % %
Intra-assay (n = 5) 2.0 2.3 0.2 7.0 15.0
25 25 2.1 8.4 1.0
100 99 7.1 7.2 20.7
Inter-assay (n = 15) 2.0 2.1 0.2 9.5 5.0
25 24 1.7 2.9 24.0
100 100 1.9 1.9 0.0
doi:10.1371/journal.pone.0053233.t004
proBNP in Human Plasma
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test. Correlation coefficients were calculated using linear regres-
sion analysis. Values of P,0.05 were considered significant.
Results
Standard curve, recovery and precision
Figure 2 shows typical standard curves for the proBNP and total
BNP assay systems. The lower detection limits were 0.04 pmol/L
(proBNP) and 0.02 pmol/L (total BNP). At these levels the mean
value (n = 8 each) of the chemiluminescence intensity (cps) was
more than twice that at 0 pmol/L (P,0.05). The working range
(coefficient of variation (CV),15%) of both assays was 0.2–
250 pmol/L in total BNP and 0.4–250 pmol/L in proBNP,
respectively.
Table 1 shows the recovery of standard proBNP and BNP,
which was estimated from the levels of glycosylated proBNP or
BNP added to clinically available plasma (endogenous total
BNP=0.3 pmol/L and proBNP=0.2 pmol/L). In the proBNP
assay system, using glycosylated proBNP as a standard, the
recovery ranged from 90–101%. In the total BNP assay system,
using BNP as the standard the recovery ranged from 85–97%. The
effect of diluting plasma samples containing 100 pmol/L glycosy-
lated proBNP or BNP is shown in Table 2. At every dilution level,
the recovery rate was good. We also investigated the effects of
dilution on plasma levels of total BNP and proBNP in three heart
failure patients. As shown in Figure 2B, the calculated total BNP
and proBNP values varied linearly with dilution (correlation
coefficients = 0.998–1.00).









proBNP BNP proBNP assay total BNP assay
50 50 58 114
100 10 113 119
10 100 8 113
doi:10.1371/journal.pone.0053233.t005
Figure 3. Gel filtration analysis of total BNP (A) and proBNP (B) in plasma from a heart failure patient. Fractions were assayed using the
total BNP (A) and proBNP (B) systems. The elution points for glycosylated proBNP, proBNP and BNP are indicated by red arrows. Black and red lines
respectively show gel filtration analyses of total BNP (A) and proBNP (B) in the same plasma sample before and after deglycosylation.
doi:10.1371/journal.pone.0053233.g003
proBNP in Human Plasma
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When we then assessed the intra- and inter-assay precision using
plasma spiked with glycosylated proBNP or BNP, we found that
the intra-assay CV ranged from 5.2%–8.0% in proBNP assay and
from 7.0%–8.4% in total BNP assay, while inter-assay CV ranged
from 5.3–7.4% in proBNP assay and from 1.9%–9.5% in total
BNP assay, respectively (Table 3, 4).
Specificity and sensitivity
We next examined the cross-reactivity between proBNP and
BNP. As shown in Table 5, the presence of BNP did not affect the
values measured with the proBNP assay system. Moreover, the
values measured with the total BNP assay system were the sum of
the BNP and proBNP even at different compositions of these two
peptides. Thus, the total BNP assay recognized both BNP and
proBNP with the same efficiency and sensitivity. Likewise, the
proBNP and total BNP assay systems recognized proBNP with the
same efficiency and sensitivity.
Gel-filtration chromatography before and after
deglycosylation procedure
Figure 3-A shows two immunoreactive BNP peaks detected
using the total BNP assay with HPLC fractions. The first peak
appeared in fractions 52–55 and the second peak in fractions 72–
75. With the same sample, one immunoreactive BNP peak was
detected by the proBNP assay (Figure 3-B); the position of that
peak was completely consistent with the proBNP peak obtained
with the total BNP assay. When subjected to gel filtration HPLC,
recombinant proBNP, glycosylated proBNP and BNP were eluted
mainly in fractions 53, 56 and 74, respectively. Treating the same
plasma sample with an enzyme cocktail catalyzing deglycosylation
shifted the first peak to fraction 54–56, which is consistent with the
proBNP peak. From these results, we conclude that total BNP
assay evaluates the sum of the glycosylated proBNP plus BNP,
while proBNP assay detects glycosylated proBNP. The proBNP
was not detected in a significant level with either assay system.
Plasma concentrations of proBNP, total BNP, and NT-
proBNP in healthy subjects and heart failure patients
Plasma total BNP, proBNP and NT-proBNP levels in different
age groups were shown in Figure 4-A, B. Plasma total BNP,
proBNP and NT-proBNP levels appeared to increase according to
the age. The older age groups (more than 50) had higher total
BNP, proBNP and NT-proBNP levels than younger age groups
(less than 50); however, there were no statistical differences in NT-
proBNP between 30,39 and 50,59. In addition, there were
significant positive relationships between plasma total BNP
(r = 0.467, p,0.001), proBNP (r = 0.491, p,0.001) and NT-
proBNP (r = 0.376, p,0.001) levels and age (Figure 5-A, B, C).
The mean total BNP and proBNP in plasma from 116 healthy
subjects were 1.461.2 pM and 1.060.7 pM, respectively
(Figure 6-A). Female had higher total BNP than male (total
BNP: 1.761.3 vs 1.161.1, P,0.05; proBNP: 1.160.8 vs
0.860.6 pM, P= 0.11) (Figure 6-C). proBNP/total BNP ratio
was lower in female than that in male. NT-proBNP was also
higher in female than those in male (Figure 6-E). The total BNP
and proBNP levels were markedly elevated in heart failure
patients, and the magnitude of the increase reflected the severity of
the patients’ condition as observed in NT-proBNP (Figure 6-A, B).
Discussion
Plasma levels of the cardiac hormone BNP increase in
proportion to the severity of heart failure. Indeed, plasma BNP
levels are used as a biomarker of heart failure, and the guidelines
in many countries recommend that BNP be used as a diagnostic
indicator of acute and chronic heart failure [1–3]. The stimuli that
increase cardiac BNP production include pressure overload,
volume overload and ischemia, as well as various cytokines and
neurohumoral factors [15]. In response to these stimuli, BNP
mRNA expression is rapidly upregulated. Following translation of
the protein, the signal peptide is removed to produce proBNP,
which is then cleaved into BNP and the NT-proBNP fragment
during secretion [15]. It is noteworthy that BNP and proBNP
could not be distinguished from one another in earlier BNP assay
systems because the anti-BNP antibodies cross-reacted with
proBNP. We therefore endeavored to develop a new assay system
that would enable separate measurement of BNP and proBNP.
Recent studies have shown that levels of uncleaved proBNP are
increased in heart failure to a greater degree than BNP [5–7,16].
Using a combination of gel filtration and an immunoenzyme
fluorescent assay for BNP, we previously found that proBNP levels
are increased in heart failure and that the proBNP/total BNP
Figure 4. Plasma Levels of total BNP, proBNP, and NT-proBNP
in different age groups. Bar graph showing the total BNP, proBNP
(A) and NT-proBNP levels (B). Values are means 6 SE., *P,0.05 vs total
BNP, proBNP, and NT-proBNP in 30,39, {P,0.05 vs total BNP, proBNP,
and NT-proBNP in 40,49.
doi:10.1371/journal.pone.0053233.g004
proBNP in Human Plasma
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ratios are higher in heart failure patients with ventricular overload
than those with atrial overload [6]. Although this protocol
provides useful information, the methodology is time-consuming
and impractical for routine assays in clinical laboratories. In
addition, recovery of proBNP may be diminished by both
extraction and the gel filtration steps [9,16]. To overcome these
problems, we developed new direct immunochemiluminescent
assays for proBNP and total BNP.
We used two monoclonal antibodies, BC203 and 18H5, to assay
proBNP. BC203 recognizes an epitope in the C-terminal of
proBNP, while 18H5 recognizes an epitope in the N-terminal.
Recent studies showed that proBNP has seven sites suitable for O-
linked oligosaccharide attachment (Ser36, Thr37, Thr44, Thr48,
Thr53, Ser58 and Thr71) within the N-terminal portion of the
peptide [14]. Because the O-linked oligosaccharide attachments
almost completely inhibit the binding of the antibody to the
peptide [17], we selected 18H5, which recognizes the N-terminal
of proBNP (a.a. 13–20) in a region not subject to glycosylation
(Figure 1). To assay total BNP, we used the monoclonal antibodies
BC203 and KY-BNP-II, as previously reported [10]. In both
assays, BC203 served as the capture antibody. Importantly,
because the affinity of 18H5 for the N-terminal portion is similar
to the affinity of KY-BNP-II for the ring structure, we are able to
calculate the proBNP/total BNP ratio. In addition, our new assays
are less time-consuming and more sensitive and accurate than
earlier ones, and the lower detection limits for total BNP
(0.02 pmol/L) and proBNP (0.04 pmol/L) enabled us to measure
plasma proBNP levels in nearly all the healthy subjects tested.
We used gel-filtration on two tandemly connected Superdex 75
columns to determine the molecular mass of plasma proBNP. As
shown in Figure 3-A,B, a single peak of proBNP was obtained in
both the total BNP and proBNP assay systems. The elution points
are consistent with that of glycosylated proBNP, but not
deglycosylated proBNP, and deglycosylation treatment significant-
ly shifted the peak rightward (Figure 3-A,B) to an elution point
consistent with proBNP. The peak immunoreactivity of proBNP
after deglycosylation was slightly smaller than before treatment,
suggesting the recovery rate of proBNP after gel-filtration is lower
than that of glycosylated proBNP, which is consistent with
proBNP being more adsorptive than glycosylated proBNP. Our
findings are also consistent with previous Western blot analyses
showing that plasma levels of glycosylated proBNP are elevated
and no substantial level of proBNP is detected in severe heart
failure [7]. Taken together, these results suggest that the major
molecular form of proBNP in the plasma of patients with heart
failure is the glycosylated form.
ProBNP is also the important molecular form of BNP in the
plasma of healthy subjects. When we previously used gel-filtration
Figure 5. The relationships between total BNP (A), proBNP (B), and NT-proBNP (C) and age.
doi:10.1371/journal.pone.0053233.g005
proBNP in Human Plasma
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Figure 6. Plasma Levels of proBNP, total BNP, and NT-proBNP in normal and heart failure. Bar graph showing the total BNP, proBNP (A)
and NT-proBNP (B) levels in healthy subjects and heart failure patients with NYHA classes 1–2 and 3–4. *P,0.05 vs total BNP and proBNP in normal,
{P,0.05 vs total BNP and proBNP in HF NYHA 1–2. Bar graph showing the total BNP, proBNP (C), proBNP/total BNP ratio (D) and NT-proBNP (E) levels
in male and female in healthy subjects. Values are means 6 SE. *P,0.05 vs male.
doi:10.1371/journal.pone.0053233.g006
proBNP in Human Plasma
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and a fluorescent immunoenzyme assay to measure BNP and
proBNP, we found that levels of BNP were slightly higher than
those of proBNP in both healthy subjects and heart failure
patients. The exact reason for the discrepancy in proBNP levels
between the earlier study and the present one is unclear; however,
the lower recovery caused by the need for extraction from plasma
on a Sep-Pak C18 cartridge may have contributed to the lower
proBNP levels in the earlier study [9,16]. Recent studies have
shown that proBNP has much less ability to induce cGMP
production in vascular smooth muscle and endothelial cells than
BNP [7,18]. This suggests that increases in the levels of the low-
activity proBNP in heart failure may contribute to the so-called
‘‘BNP paradox’’ [19]. That is, administration of exogenous
recombinant human BNP to heart failure patients has a substantial
clinical and hemodynamic impact, despite the presence of high
levels of immunoreactive BNP in their plasma, as measured with
commercially used BNP assays.
In the current study, we showed that total BNP and NT-
proBNP increased with aging, which are consistent with the
previous studies. In addition, the current study first showed that
plasma proBNP level increased with aging. However, there were
no statistical differences in NT-proBNP between 30,39 and
50,59, whereas there were significant differences in total and
proBNP between 30,39 and 50,59, suggesting that total and
proBNP are more sensitive than NT-proBNP. In addition, total
and proBNP seemed to be well correlated with age (r = 0.467.
0.491, each) than NT-proBNP (r = 0.376). Thus, total BNP and
proBNP may be better marker in discriminating the effect of age
than NT-proBNP. Increased myocardial mass and/or reduction of
renal clearance of natriuretic peptides with aging may be one of
the possible reason for increased BNP and NT-BNP with aging;
however, exact mechanism for it still remains unknown and
further study is necessary to investigate the relationships between
proBNP and aging.
We also analyzed the effects of gender on proBNP, total BNP,
proBNP/total BNP ratio and NT-proBNP. Interestingly, in female
higher total BNP and NT-proBNP and lower proBNP/total BNP
ratio without changing of proBNP was observed. Calculated BNP
(total BNP - proBNP) was also increased. This finding may be
explained that increased proBNP production and higher process-
ing rate. Further study is necessary to elucidate the mechanism of
increased total BNP and NT-proBNP and lower proBNP/total
BNP ratio without changing of proBNP in female.
In summary, we have developed rapid and precise immuno-
chemiluminescent assay systems for routine determination of total
BNP and proBNP levels in human plasma. Using these assay
systems we showed that in addition to BNP, considerable amount
of proBNP circulates in both healthy subjects and heart failure
patients. The precise relation of the proBNP/total BNP ratio to
heart failure remains unknown, as does whether the heart mainly
secretes proBNP. Likewise, the effects of age, sex and renal
function on proBNP levels remain unknown. We anticipate our
new assays for the proBNP and total BNP will be helpful for
addressing each of those issues.
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